Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$774M |
| 2 |
Intuitive Surgical
ISRG
|
+$654M |
| 3 |
S&P Global
SPGI
|
+$464M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$326M |
| 5 |
CELG
Celgene Corp
CELG
|
+$243M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FedEx
FDX
|
+$591M |
| 2 |
Broadcom
AVGO
|
+$550M |
| 3 |
Monster Beverage
MNST
|
+$408M |
| 4 |
Booking.com
BKNG
|
+$377M |
| 5 |
McDonald's
MCD
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.27% |
| 2 | Consumer Discretionary | 16.23% |
| 3 | Healthcare | 15.49% |
| 4 | Financials | 12.97% |
| 5 | Communication Services | 11.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Cardlytics
CDLX
$22.1M
| $20M | 0.02% |
79,850
-778
| -1% | -$167K |
|
|
HMHC
402
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $19.9M | 0.02% |
2,836,729
-241,525
| -8% | -$1.63M |
|
403
Honeywell
HON
$76.7B
| $19.2M | 0.02% |
127,936
+56,406
| +79% | +$7.99M |
|
404
Owens Corning
OC
$11.2B
| $19.2M | 0.02% |
353,941
-5,874
| -2% | -$354K |
|
|
MRNS
405
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $19M | 0.02% |
475,631
-213,708
| -31% | -$6.08M |
|
|
XOG
406
DELISTED
Extraction Oil & Gas, Inc. Common Stock
XOG
| $18.8M | 0.02% |
+1,662,450
| New | +$21.1M |
|
|
AXE
407
DELISTED
Anixter International Inc
AXE
| $18.5M | 0.02% |
263,497
-353,922
| -57% | -$24.8M |
|
408
Independence Realty Trust
IRT
$3.93B
| $18.4M | 0.02% |
1,749,949
-29,077
| -2% | -$297K |
|
|
GOLD
409
DELISTED
Randgold Resources Ltd
GOLD
| $18.4M | 0.02% |
260,298
-17,977
| -6% | -$1.23M |
|
410
Healthcare Services Group
HCSG
$1.58B
| $18.3M | 0.02% |
450,899
+155,495
| +53% | +$6.46M |
|
|
ABMD
411
DELISTED
Abiomed Inc
ABMD
| $18.3M | 0.02% |
+40,682
| New | +$16M |
|
412
B&G Foods
BGS
$293M
| $18.2M | 0.02% |
664,578
-464
| -0.1% | -$14.4K |
|
413
Monro
MNRO
$421M
| $18.1M | 0.02% |
260,279
+10
| +0% | +$684 |
|
414
Philip Morris
PM
$299B
| $17.4M | 0.02% |
+213,945
| New | +$17.6M |
|
|
PXD
415
DELISTED
Pioneer Natural Resource Co.
PXD
| $17.4M | 0.02% |
99,974
-7,078
| -7% | -$1.27M |
|
|
BPMC
416
DELISTED
Blueprint Medicines
BPMC
| $17.4M | 0.02% |
222,540
+1,658
| +0.8% | +$115K |
|
|
QTS
417
DELISTED
QTS REALTY TRUST, INC.
QTS
| $17.3M | 0.02% |
405,339
-7
| -0% | -$305 |
|
418
Huron Consulting
HURN
$2.61B
| $17.2M | 0.02% |
347,400
+4,683
| +1% | +$219K |
|
|
FOCS
419
DELISTED
Focus Financial Partners Inc. Class A
FOCS
| $17.1M | 0.02% |
+360,868
| New | +$15.4M |
|
420
Newmont
NEM
$101B
| $17.1M | 0.02% |
564,663
-39,523
| -7% | -$1.34M |
|
421
Tenaris
TS
$28.6B
| $17M | 0.02% |
507,211
+50,151
| +11% | +$1.74M |
|
422
Core Laboratories
CLB
$477M
| $16.9M | 0.02% |
145,795
-10,739
| -7% | -$1.21M |
|
423
Vodafone
VOD
$37.2B
| $16.7M | 0.02% |
770,399
-2,134,554
| -73% | -$49.6M |
|
424
Acadia Healthcare
ACHC
$2.62B
| $16.7M | 0.02% |
473,392
+95,946
| +25% | +$3.82M |
|
425
Ocular Therapeutix
OCUL
$1.85B
| $16.1M | 0.01% |
2,335,989
+16,734
| +0.7% | +$105K |
|
Similar funds
Jennison Associates's Q3 2018 Portfolio in Review
As of Q3 2018, Jennison Associates held 739 positions worth $109B, up 5.9% from $103B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jennison Associates's Q3 2018 filing shows 86 new, 214 increased, 352 reduced and 81 closed positions. Its largest new stake was Tiffany & Co.: 1,169,094 shares worth $151M. The largest sale was FedEx, an estimated $591M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Jennison Associates's largest Q3 2018 buy was Tiffany & Co.: 1,169,094 shares worth $151M.
- Jennison Associates added most to AstraZeneca in Q3 2018, an estimated $774M increase.
- Jennison Associates's biggest Q3 2018 reduction was FedEx, cutting an estimated $591M.
- Jennison Associates fully exited Cheniere Energy Partners LP Holdings LLC in Q3 2018, selling an estimated $134M.
- Jennison Associates's ten largest holdings make up 30% of its $109B portfolio in Q3 2018.
- Jennison Associates opened 86 new positions and closed 81 in Q3 2018.
- Jennison Associates's portfolio value rose 5.9% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q3 2018, filed 8 Nov 2018.